image
Healthcare - Drug Manufacturers - General - NYSE - US
$ 14.585
-2.18 %
$ 3.76 B
Market Cap
4.38
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one OGN stock under the worst case scenario is HIDDEN Compared to the current market price of 14.6 USD, Organon & Co. is HIDDEN

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one OGN stock under the base case scenario is HIDDEN Compared to the current market price of 14.6 USD, Organon & Co. is HIDDEN

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one OGN stock under the best case scenario is HIDDEN Compared to the current market price of 14.6 USD, Organon & Co. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
6.26 B REVENUE
1.44%
1.33 B OPERATING INCOME
-10.22%
1.02 B NET INCOME
11.56%
799 M OPERATING CASH FLOW
-6.88%
-260 M INVESTING CASH FLOW
38.10%
-569 M FINANCING CASH FLOW
-31.41%
1.58 B REVENUE
-1.56%
390 M OPERATING INCOME
1.04%
359 M NET INCOME
84.10%
141 M OPERATING CASH FLOW
-57.53%
142 M INVESTING CASH FLOW
408.22%
-78 M FINANCING CASH FLOW
41.79%
Balance Sheet Organon & Co.
image
Current Assets 4.51 B
Cash & Short-Term Investments 693 M
Receivables 1.74 B
Other Current Assets 2.07 B
Non-Current Assets 7.55 B
Long-Term Investments 0
PP&E 1.18 B
Other Non-Current Assets 6.37 B
Current Liabilities 2.92 B
Accounts Payable 1.31 B
Short-Term Debt 9 M
Other Current Liabilities 1.6 B
Non-Current Liabilities 9.21 B
Long-Term Debt 8.88 B
Other Non-Current Liabilities 334 M
EFFICIENCY
Earnings Waterfall Organon & Co.
image
Revenue 6.26 B
Cost Of Revenue 2.52 B
Gross Profit 3.75 B
Operating Expenses 2.42 B
Operating Income 1.33 B
Other Expenses 304 M
Net Income 1.02 B
RATIOS
59.84% GROSS MARGIN
59.84%
21.19% OPERATING MARGIN
21.19%
16.33% NET MARGIN
16.33%
-1461.43% ROE
-1461.43%
8.48% ROA
8.48%
22.05% ROIC
22.05%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Organon & Co.
image
Net Income 1.02 B
Depreciation & Amortization 236 M
Capital Expenditures -261 M
Stock-Based Compensation 101 M
Change in Working Capital -155 M
Others 203 M
Free Cash Flow 538 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Organon & Co.
image
Wall Street analysts predict an average 1-year price target for OGN of $24 , with forecasts ranging from a low of $24 to a high of $24 .
OGN Lowest Price Target Wall Street Target
24 USD 64.55%
OGN Average Price Target Wall Street Target
24 USD 64.55%
OGN Highest Price Target Wall Street Target
24 USD 64.55%
4. DIVIDEND ANALYSIS
1.50% DIVIDEND YIELD
0.28 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Organon & Co.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Feb 22, 2024
Bought 49.9 K USD
Weaver Kirke
Gen. Counsel & Corp. Secy.
+ 2720
18.3599 USD
3 years ago
Aug 19, 2021
Bought 101 K USD
Francisco Ma. Fatima
Director
+ 3000
33.79 USD
7. News
High-Yield Healthcare: 3 Stocks With Strong Dividends When it comes to dividend performers, healthcare usually takes a backseat to options like REITs and energy stocks. However, the sector's resilience, driven by aging populations and consistent demand for medical services, makes it an underrated source of steady income. marketbeat.com - 2 weeks ago
Organon & Co. (OGN) Q4 2024 Earnings Call Transcript Organon & Co. (NYSE:OGN ) Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Juan Camilo Arjona Ferreira - Head of R&D Matt Walsh - CFO Conference Call Participants Terence Flynn - Morgan Stanley Michael Nedelcovych - TD Cowen Ethan Brown - JPMorgan David Amsellem - Piper Sandler Balaji Prasad - Barclays Jason Gerberry - Bank of America Umer Raffat - Evercore ISI Operator Thank you for standing by. My name is Celine and I will be your conference operator today. seekingalpha.com - 2 weeks ago
Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 2 weeks ago
Organon (OGN) Q4 Earnings and Revenues Beat Estimates Organon (OGN) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.88 per share a year ago. zacks.com - 2 weeks ago
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024 JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces Q4 2024 and Full Year 2024 earnings results, ending December 31, 2024. businesswire.com - 2 weeks ago
Why Organon (OGN) Dipped More Than Broader Market Today Organon (OGN) concluded the recent trading session at $14.62, signifying a -1.81% move from its prior day's close. zacks.com - 3 weeks ago
Organon (OGN) Rises Higher Than Market: Key Facts The latest trading day saw Organon (OGN) settling at $15.97, representing a +0.82% change from its previous close. zacks.com - 1 month ago
Organon (OGN) Increases Despite Market Slip: Here's What You Need to Know Organon (OGN) closed at $16.26 in the latest trading session, marking a +1.82% move from the prior day. zacks.com - 1 month ago
Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025 JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025. businesswire.com - 1 month ago
Organon (OGN) Surpasses Market Returns: Some Facts Worth Knowing Organon (OGN) closed the most recent trading day at $15.88, moving +0.89% from the previous trading session. zacks.com - 1 month ago
Organon: A Tricky 2025 Awaits, But I'm Happy With A >7% Dividend Yield Organon has faced significant price volatility and underperformance since its spin-off from Merck, with shares down ~50% since 2021. Key products like Nexplanon and VTAMA are crucial for future growth, but uncertainties and competition pose significant risks to revenue projections. Organon's high debt and interest payments are significant concerns, despite low P/S and P/E ratios suggesting undervaluation, and a strong dividend yield. seekingalpha.com - 1 month ago
Organon & Co. (OGN) JPMorgan Annual Healthcare Conference - (Transcript) Organon & Co. (NYSE:OGN ) JPMorgan Annual Healthcare Conference Call January 13, 2025 6:45 PM ET Company Participants Kevin Ali - Chief Executive Officer Matthew Walsh - Chief Financial Officer Conference Call Participants Chris Schott - JPMorgan Chris Schott Good afternoon, everybody. I'm Chris Schott from JPMorgan and it's my pleasure to be hosting this fireside chat with the Organon management team. seekingalpha.com - 1 month ago
8. Profile Summary

Organon & Co. OGN

image
COUNTRY US
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 3.76 B
Dividend Yield 1.50%
Description Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
Contact 30 Hudson Street, Jersey City, NJ, 07302 https://www.organon.com
IPO Date May 14, 2021
Employees 10000
Officers Mr. Joseph T. Morrissey Jr. Executive Vice President and Head of Manufacturing & Supply Mr. Aaron Falcione Executive Vice President & Chief Human Resources Officer Ms. Rebecca Lowell Edwards Chief Communications Officer Ms. Susan O'Neal Chief Ethics & Compliance Officer Mr. Kirke Weaver Executive Vice President, General Counsel & Corporate Secretary Ms. Jennifer Halchak Head of Investor Relations Mr. Daniel Karp Executive Vice President of Corporate Development Mr. Matthew M. Walsh C.F.A. Executive Vice President & Chief Financial Officer Mr. Vittorio Nisita Executive Vice President & Head of Global Business Services Mr. Kevin Ali Chief Executive Officer & Director